Marc Frahm
Stock Analyst at TD Cowen
(0.19)
# 4,458
Out of 5,154 analysts
15
Total ratings
16.67%
Success rate
-20.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Buy | $101 → $128 | $95.94 | +33.42% | 4 | Jan 13, 2026 | |
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $3.15 | - | 2 | Jan 8, 2025 | |
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $13.57 | -33.68% | 3 | Aug 6, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $15.74 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.53 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $99.41 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $13.84 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $21.20 | - | 1 | Jun 21, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.15 | - | 1 | Feb 24, 2020 |
Incyte
Jan 13, 2026
Maintains: Buy
Price Target: $101 → $128
Current: $95.94
Upside: +33.42%
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $3.15
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $13.57
Upside: -33.68%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.74
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.53
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $99.41
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.84
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.20
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.15
Upside: -